Phaseline

Companies › Zydus Therapeutics

Zydus Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 1, 1 Phase 2; Neurology, Gastroenterology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Saroglitazar
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist
PPARA, PPARGPhase 3Primary Biliary Cholangitis; Hepatic Impairment; Cholestatic Liver DiseaseDec 2026
Usnoflast–Phase 2Amyotrophic Lateral Sclerosis (ALS)Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05045482SaroglitazarPhase 1Hepatic ImpairmentGastroenterologyDec 2026
NCT06825559SaroglitazarPhase 1Cholestatic Liver DiseaseGastroenterologyDec 2026
NCT06427395SaroglitazarPhase 3Primary Biliary CholangitisGastroenterologyApr 2027
NCT07023835UsnoflastPhase 2Amyotrophic Lateral Sclerosis (ALS)NeurologyMar 2028
NCT07424677SaroglitazarPhase 3Primary Biliary CholangitisGastroenterologyJul 2028
NCT07216235SaroglitazarPhase 3Primary Biliary CholangitisGastroenterologyNov 2032

Targets

PPARA (1) PPARG (1)

Companies with the same targets

RDC Clinical Inventiva Pharma Ipsen Kowa Company Flare Therapeutics Boryung Pharmaceutical Minoryx Therapeutics Dong Wha Pharmaceutical

Companies built like this

Inventiva Pharma Minoryx Therapeutics Shin Poong Pharmaceutical GRIN Therapeutics Larimar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.